A new tumorgraft panel to accelerate precision medicine in prostate cancer

BackgroundDespite the significant advances in the management of advanced prostate cancer (PCa), metastatic PCa is currently considered incurable. For further investigations in precision treatment, the development of preclinical models representing the complex prostate tumor heterogeneity are mandato...

Descrición completa

Detalles Bibliográficos

Principais autores:	Claire Béraud, Nadege Bidan, Myriam Lassalle, Hervé Lang, Véronique Lindner, Clémentine Krucker, Julien Masliah-Planchon, Eric Potiron, Philippe Lluel, Thierry Massfelder, Yves Allory, Yolande Misseri
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Oncology
Assuntos:	PDX prostate cancer neuroendocine tumors genomic characteristics PARP inhibitor metabolism
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1130048/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!